Researchers from Meiji Seika Pharma Co. Ltd. and affiliated organizations reported the discovery and preclinical evaluation of a novel PD-1 agonist antibody, HM-266, being developed for the treatment of various inflammatory disorders, including autoimmune diseases.
Ono Pharmaceutical Co. Ltd. has entered an option and research collaboration agreement with Monash University to discover and develop antibodies targeting G protein-coupled receptors (GPCRs) with the aim of creating novel therapeutics for the treatment of autoimmune and inflammatory diseases.
Researchers from Neoleukin Therapeutics Inc. have described NEO-TRA1, a novel CD25-targeted de novo non-α agonist of the IL-2 receptor (IL-2R) designed to selectively expand Tregs.
Dialing down the immune response remains at the heart of myriad drug development efforts in autoimmune disease. Targeting cytokines, such as tumor necrosis factor alpha or interleukin-12 (IL-12) and IL-23, IL-6, or IL-17, or modulating immune cell trafficking by targeting sphingosine-1-phosphate receptor or integrins, are therapeutic mainstays. But chronic immunosuppression and all its attendant safety concerns is the price that many autoimmune disease patients pay to remain in remission.
Apogee Therapeutics Inc. emerged from stealth with $169 million in financing and a pipeline of four preclinical antibody development programs that take aim at major immunological and inflammatory disorders.
Abbvie Inc. and Hotspot Therapeutics Inc. have entered into an exclusive worldwide collaboration and option to license agreement for Hotspot's discovery-stage interferon regulatory factor 5 (IRF5) program for the treatment of autoimmune diseases.
Research conducted at Inflection Biosciences Ltd. and affiliated organizations has led to the discovery of a novel pan-PIM kinase inhibitor, IBL-101, as a potential therapeutic candidate for autoimmune disease, including psoriasis.
Does cancer cause autoimmune disease or is it the other way around? In looking at the question of which comes first, the chicken or the egg, researchers at the Garvan Institute of Medical Research in Australia found that a genetic mutation that alters immune cells in leukemia is behind certain autoimmune disorders.
A research team at Duality Biologics (Suzhou) Co. Ltd. has discovered a novel anti-TNF-α monoclonal antibody-drug conjugate (ADC), DB-2306, as a potential therapeutic candidate for the treatment of autoimmune disease.